Walvax BioTech (300142) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.003x

Based on the latest financial reports, Walvax BioTech (300142) has a cash flow conversion efficiency ratio of -0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-33.52 Million ≈ $-4.91 Million USD) by net assets (CN¥10.94 Billion ≈ $1.60 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Walvax BioTech (300142) strategic investment index to assess the company's strategic physical and investment asset allocation.

Walvax BioTech - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Walvax BioTech's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Walvax BioTech book value and equity for net asset value and shareholders' equity analysis.

Walvax BioTech Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Walvax BioTech ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Fujian Sunner Development Co Ltd SHE:002299	0.145x
Hypera S.A SA:HYPE3	0.014x
Metro Brands Limited NSE:METROBRAND	0.076x
Shenzhen Sed Industry Co Ltd SHE:000032	-0.015x
GoTo Gojek Tokopedia PT JK:GOTO	0.016x
Brookdale Senior Living Inc NYSE:BKD	-0.383x
DOF Group ASA OL:DOFG	0.258x
Grand Plastic Technology TWO:3131	0.229x

Annual Cash Flow Conversion Efficiency for Walvax BioTech (2007–2025)

The table below shows the annual cash flow conversion efficiency of Walvax BioTech from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see 300142 company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥9.81 Billion ≈ $1.44 Billion	CN¥494.37 Million ≈ $72.34 Million	0.050x	-44.07%
2024-12-31	CN¥11.51 Billion ≈ $1.68 Billion	CN¥1.04 Billion ≈ $151.68 Million	0.090x	-9.47%
2023-12-31	CN¥11.40 Billion ≈ $1.67 Billion	CN¥1.13 Billion ≈ $165.91 Million	0.099x	-8.99%
2022-12-31	CN¥10.99 Billion ≈ $1.61 Billion	CN¥1.20 Billion ≈ $175.82 Million	0.109x	+55.00%
2021-12-31	CN¥10.00 Billion ≈ $1.46 Billion	CN¥705.28 Million ≈ $103.20 Million	0.071x	+384.76%
2020-12-31	CN¥7.85 Billion ≈ $1.15 Billion	CN¥114.19 Million ≈ $16.71 Million	0.015x	+32.94%
2019-12-31	CN¥5.67 Billion ≈ $829.11 Million	CN¥62.02 Million ≈ $9.08 Million	0.011x	+188.30%
2018-12-31	CN¥5.26 Billion ≈ $770.02 Million	CN¥-65.23 Million ≈ $-9.54 Million	-0.012x	-335.34%
2017-12-31	CN¥3.56 Billion ≈ $520.57 Million	CN¥-10.13 Million ≈ $-1.48 Million	-0.003x	+88.84%
2016-12-31	CN¥3.52 Billion ≈ $515.62 Million	CN¥-89.94 Million ≈ $-13.16 Million	-0.026x	-11.19%
2015-12-31	CN¥3.02 Billion ≈ $442.47 Million	CN¥-69.41 Million ≈ $-10.16 Million	-0.023x	-11.83%
2014-12-31	CN¥3.21 Billion ≈ $470.01 Million	CN¥-65.93 Million ≈ $-9.65 Million	-0.021x	+50.45%
2013-12-31	CN¥2.94 Billion ≈ $429.99 Million	CN¥-121.73 Million ≈ $-17.81 Million	-0.041x	-267.52%
2012-12-31	CN¥3.17 Billion ≈ $463.81 Million	CN¥78.38 Million ≈ $11.47 Million	0.025x	-27.05%
2011-12-31	CN¥2.71 Billion ≈ $397.06 Million	CN¥91.98 Million ≈ $13.46 Million	0.034x	-0.28%
2010-12-31	CN¥2.55 Billion ≈ $373.28 Million	CN¥86.71 Million ≈ $12.69 Million	0.034x	-92.77%
2009-12-31	CN¥174.69 Million ≈ $25.56 Million	CN¥82.18 Million ≈ $12.03 Million	0.470x	+912.58%
2008-12-31	CN¥98.36 Million ≈ $14.39 Million	CN¥-5.69 Million ≈ $-833.30K	-0.058x	-103.21%
2007-12-31	CN¥17.66 Million ≈ $2.58 Million	CN¥31.85 Million ≈ $4.66 Million	1.804x	--

About Walvax BioTech

SHE:300142 China Drug Manufacturers - Specialty & Generic

Market Cap

$3.10 Billion

CN¥21.19 Billion CNY

Market Cap Rank

#4911 Global

#911 in China

Share Price

CN¥13.25

Change (1 day)

-4.88%

52-Week Range

CN¥10.15 - CN¥16.00

All Time High

CN¥93.63